A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis
The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed
once-daily, in subjects with allergic conjunctivitis and to record any adverse events as
described by the subjects as a part of this post marketing surveillance study.
Comparing Patient Satisfaction With Pataday or Bepreve
McCabe Vision Center
The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine
hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution
1.5%) two times a day (BID).
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™
(Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular
itching associated with allergic conjunctivitis.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.